产品详情
简单介绍：
Anti-CAB39L抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-CAB39L抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-CAB39L
Cat. Number:
Anti-CAB39L抗体KL-6802R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Peutz-Jegers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. Mutations in the gene encoding the serine/threonine kinase LKB1 (also designated STK11) are the cause of PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-α
Anti-CAB39L抗体(STRAD α) pseudo kinase and the calcium binding protein 39 (MO25, also known as CAB39). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK). CAB39L (calcium binding protein 39-like), also known as MO25L (MO25-like) or MO2L, is a 337 amino acid protein that is similar to MO25 and is found in the serum of nearly half of all patients diagnosed with acute monocytic leukemia. This suggests a role for CAB39L in carcinogenesis.
Also known as:
Antigen MLAA-34;
Anti-CAB39L抗体CAB39-LIKE PROTEIN; Cab39l; Calcium-binding protein 39-like; CB39L_HUMAN; MO25-BETA; Mo25-like protein; MO2L; sarcoma antigen NY-SAR-79; U937-associated antigen.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human CAB39L.
●
Predicted Molecular Weight: 39kDa.
Storage:
Shipped at 4℃, Store at -20℃
Anti-CAB39L抗体(Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutions must Anti-CAB39L抗体be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must Anti-CAB39L抗体be determined by the end user.
kl424Mu02 八聚体结合转录因子4(OCT4)多克隆抗体 Polyclonal Antibody to Octamer Binding Transcription Factor 4 (OCT4)
kl425Mu02 突触素(SYP)多克隆抗体 Polyclonal Antibody to Synaptophysin (SYP)
kl431Mu02 颗粒酶M(GZMM)多克隆抗体 Polyclonal Antibody to Granzyme M (GZMM)
kl433Mu02 蛋白激酶Cδ(PKCδ)多克隆抗体 Polyclonal Antibody to Protein Kinase C Delta (PKCd)
kl437Mu02 雌**受体β(ERβ)多克隆抗体 Polyclonal Antibody to Estrogen Receptor Beta (ERb)
kl438Mu02 促生长**释放**(GHRH)多克隆抗体 Polyclonal Antibody to Growth Hormone Releasing Hormone (GHRH)
kl439Mu02 蛋白激酶Cε(PKCε)多克隆抗体 Polyclonal Antibody to Protein Kinase C Epsilon (PKCe)
kl439Ra01 蛋白激酶Cε(PKCε)多克隆抗体 Polyclonal Antibody to Protein Kinase C Epsilon (PKCe)
kl442Mu02 阻抑素(PHB)多克隆抗体 Polyclonal Antibody to Prohibitin (PHB)
kl446Mu02 抑制素βC(INHβC)多克隆抗体 Polyclonal Antibody to Inhibin Beta C (INHbC)
kl448Gu01 胰岛素(INS)多克隆抗体 Polyclonal Antibody to Insulin (INS)
kl448Mu02 胰岛素(INS)多克隆抗体 Polyclonal Antibody to Insulin (INS)
kl449Mu02 胱天蛋白酶7(CASP7)多克隆抗体 Polyclonal Antibody to Caskle 7 (CASP7)
kl451Mu02 激肽释放酶5(KLK5)多克隆抗体 Polyclonal Antibody to Kallikrein 5 (KLK5)
kl469Mu02 内皮脂肪酶(LIPG)多克隆抗体 Polyclonal Antibody to Likle, Endothelial (LIPG)
kl471Ga01 骨钙素(OC)多克隆抗体 Polyclonal Antibody to Osteocalcin (OC)
kl471Mu02 骨钙素(OC)多克隆抗体 Polyclonal Antibody to Osteocalcin (OC)
